Patents Assigned to CARSGEN THERAPEUTICS CO., LTD.
  • CELLULAR IMMUNOTHERAPY COMBINATION
    Publication number: 20220152101
    Abstract: Disclosed is a tumor treatment method, wherein immune effector cells and Gemcitabine are administered to an individual with tumor, and the immune effector cells express receptors having a tumor-specific antigen. Also disclosed is a tumor treatment kit, wherein the kit comprises 1) immune effector cells expressing receptors that recognize tumor antigens; 2) Gemcitabine; 3) a container for containing the substances of 1) and 2) described above; and 4) drug administration instructions for using the kit to treat a tumor.
    Type: Application
    Filed: January 7, 2020
    Publication date: May 19, 2022
    Applicants: CARSGEN THERAPEUTICS CO., LTD., SHANGHAI CANCER INSTITUTE
    Inventors: Zonghai LI, Xiuqi WU
  • COMBINATION OF CELLULAR IMMUNOTHERAPY
    Publication number: 20210113614
    Abstract: Provided in the present invention is a method for treating tumor. An immune effector cell and a second treatment agent are applied to individual suffering from tumor, wherein the immune effector cell expresses a receptor for recognizing tumor antigen, and wherein the second treatment agent is a compound of formula I or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 2, 2019
    Publication date: April 22, 2021
    Applicants: CARSGEN THERAPEUTICS CO., LTD., SHANGHAI CANCER INSTITUTE
    Inventors: Zonghai LI, Xiuqi WU
  • Tumor-specific anti-EGFR antibody and application thereof
    Patent number: 10927176
    Abstract: The present invention provides a tumor-specific anti-EGFR antibody and application thereof. The antibody can be used for preparing targeted antitumor drugs and tumor diagnosis drugs.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: February 23, 2021
    Assignee: CARSGEN THERAPEUTICS CO., LTD.
    Inventors: Huamao Wang, Bo Song
  • Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
    Patent number: 10793641
    Abstract: The present invention provides fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: October 6, 2020
    Assignee: CARSGEN THERAPEUTICS CO., LTD.
    Inventors: Huamao Wang, Bo Song, Peng Wang
  • ANTIBODY TARGETING IL-13RA2 AND USE THEREOF
    Publication number: 20190359723
    Abstract: Provided is an antibody that specifically recognizes IL-13RA2, which can be used in the manufacture of a targeting anti-tumor medicament as well as a medicament for diagnosing a tumor.
    Type: Application
    Filed: February 8, 2018
    Publication date: November 28, 2019
    Applicants: CARSGEN THERAPEUTICS CO., LTD., CARSGEN THERAPEUTICS CO., LTD.
    Inventors: Peng WANG, Huamao WANG
  • CHIMERIC ANTIGEN RECEPTOR-MODIFIED IMMUNE EFFECTOR CELL CARRYING PD-L1 BLOCKING AGENT
    Publication number: 20180327470
    Abstract: Provided is a chimeric antigen receptor-modified immune effector cell carrying a procedural death ligand 1 (PD-L1) blocking agent. Also provided is a method for secreting and expressing a PD-L1 blocking agent using the immune effector cell as a carrier to improve the anti-tumour effect of the chimeric antigen receptor-modified immune effector cell.
    Type: Application
    Filed: October 31, 2016
    Publication date: November 15, 2018
    Applicants: CARSGEN THERAPEUTICS CO., LTD., SHANGHAI CANCER INSTITUTE
    Inventors: Zonghai Li, Zeyan Pan, Zhimin Shi, Bo Song, Peng Wang
  • Multi-functional antibody polypeptide for cryptic epitope of epidermal growth factor receptor and T cell antigen
    Patent number: 10023639
    Abstract: Multi-functional antibody polypeptide comprises: (a) a first functional domain, specifically recognizing a cryptic epitope formed by 287th to 302nd amino acid sequence of the EGFR, shown as SEQ ID NO:1, and (b) a second functional domain, specifically recognizing the surface antigen of a human T cell.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: July 17, 2018
    Assignee: CARSGEN THERAPEUTICS CO., LTD.
    Inventors: Zonghai Li, Hua Jiang, Bizhi Shi, Huamao Wang, Juan Kong, Huiping Gao